New therapeutic targets in the management of urothelial carcinoma of the bladder

herapeutic targets in the management of urothelial carcinoma of the bladder Review (442) Total Article Views Authors: Sverrisson EF, Espiritu PN, Spiess PE Video abstract presented by Philippe E Spiess Views: 28 Published Date March 2013 Volume 2013:5 Pages 53 - 65 DOI: http://dx.doi.org/10.2147/RRU.S29131 Received: 08 December 2012 Accepted: 25 January 2013 Published: 01 March 2013 Einar F Sverrisson, Patrick N Espiritu, Philippe E Spiess Department of Genitourinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA Abstract: Urothelial carcinoma of the bladder, despite the myriad of treatment approaches and our progressively increasing knowledge into its disease processes, remains one of the most clinically challenging problems in modern urological clinical practice. New therapies target biomolecular pathways and cellular mediators responsible for regulating cell growth and metabolism, both of which are frequently overexpressed in malignant urothelial cells, with the intent of inducing cell death by limiting cellular metabolism and growth, creating an immune response, or selectively delivering or activating a cytotoxic agent. These new and novel therapies may offer a potential for reduced toxicity and an encouraging hope for better treatment outcomes, particularly for a disease often refractory or not amenable to the current therapeutic approaches.